AzaSite Plus: Phase III started

InSite began the double-blind, U.S. DOUBle Phase III trial in about 900 patients to evaluate AzaSite Plus and DexaSite. Patients will receive AzaSite Plus, DexaSite, AzaSite or the DuraSite vehicle twice daily for 14 days. InSite has an SPA from FDA for DOUBle. ...